

Hebert Alberto Vargas

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/7740576/publications.pdf>

Version: 2024-02-01

126
papers

6,730
citations

66343
42
h-index

66911
78
g-index

130
all docs

130
docs citations

130
times ranked

9204
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	7.1	426
2	Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness. Radiology, 2011, 259, 775-784.	7.3	377
3	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq1 1 0.784314 rgBT /Over	1.9	372
4	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	28.9	368
5	Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. European Radiology, 2015, 25, 2840-2850.	4.5	322
6	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	286
7	Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. European Radiology, 2016, 26, 1606-1612.	4.5	279
8	Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate Cancer. Journal of Urology, 2012, 188, 1732-1738.	0.4	201
9	Intravoxel Incoherent Motionâ€‘derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses. Radiology, 2016, 280, 446-454.	7.3	136
10	Unraveling tumorâ€‘immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	21.4	136
11	Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis. European Radiology, 2017, 27, 2903-2915.	4.5	128
12	MR Imaging of Treated Prostate Cancer. Radiology, 2012, 262, 26-42.	7.3	120
13	Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology</i> Scientific Expert Panel. Radiology, 2021, 300, E323-E327.	7.3	117
14	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
15	Multiparametric Prostate MR Imaging with T2-weighted, Diffusion-weighted, and Dynamic Contrast-enhanced Sequences: Are All Pulse Sequences Necessary to Detect Locally Recurrent Prostate Cancer after Radiation Therapy?. Radiology, 2013, 268, 440-450.	7.3	109
16	Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. European Journal of Radiology, 2014, 83, 1169-1176.	2.6	109
17	Normal Central Zone of the Prostate and Central Zone Involvement by Prostate Cancer: Clinical and MR Imaging Implications. Radiology, 2012, 262, 894-902.	7.3	104
18	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 306-315.	5.4	97

#	ARTICLE	IF	CITATIONS
19	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017, 27, 3991-4001.	4.5	92
20	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
21	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. <i>Radiology</i> , 2014, 271, 220-229.	7.3	88
22	Renal Cortical Tumors: Use of Multiphasic Contrast-enhanced MR Imaging to Differentiate Benign and Malignant Histologic Subtypes. <i>Radiology</i> , 2012, 264, 779-788.	7.3	86
23	Molecular Imaging of Prostate Cancer. <i>Radiographics</i> , 2016, 36, 142-159.	3.3	83
24	Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. <i>Radiology</i> , 2012, 265, 478-487.	7.3	81
25	Value of the Hemorrhage Exclusion Sign on T1-weighted Prostate MR Images for the Detection of Prostate Cancer. <i>Radiology</i> , 2012, 263, 751-757.	7.3	80
26	Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. <i>European Radiology</i> , 2011, 21, 1970-1978.	4.5	79
27	Pelvic Imaging Following Chemotherapy and Radiation Therapy for Gynecologic Malignancies. <i>Radiographics</i> , 2010, 30, 1843-1856.	3.3	74
28	Diagnosis of Extracapsular Extension of Prostate Cancer on Prostate MRI: Impact of Second-Opinion Readings by Subspecialized Genitourinary Oncologic Radiologists. <i>American Journal of Roentgenology</i> , 2015, 205, W73-W78.	2.2	74
29	Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score. <i>Clinical Cancer Research</i> , 2014, 20, 3705-3711.	7.0	69
30	Prospective evaluation of MRI, 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. <i>European Journal of Radiology</i> , 2012, 81, 4131-4137.	2.6	66
31	Detection of Clinically Significant Prostate Cancer: Short Dual-echo Pulse Sequence versus Standard Multiparametric MR Imaging—A Multireader Study. <i>Radiology</i> , 2017, 284, 725-736.	7.3	62
32	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Journal of Urology</i> , 2020, 203, 1122-1127.	0.4	58
33	Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. <i>Radiology</i> , 2017, 285, 482-492.	7.3	52
34	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	1.0	52
35	The Incremental Value of Contrast-Enhanced MRI in the Detection of Biopsy-Proven Local Recurrence of Prostate Cancer After Radical Prostatectomy: Effect of Reader Experience. <i>American Journal of Roentgenology</i> , 2012, 199, 360-366.	2.2	51
36	Association between Morphologic CT Imaging Traits and Prognostically Relevant Gene Signatures in Women with High-Grade Serous Ovarian Cancer: A Hypothesis-generating Study. <i>Radiology</i> , 2015, 274, 742-751.	7.3	50

#	ARTICLE	IF	CITATIONS
37	Ovarian-Adnexal Reporting Lexicon for MRI: A White Paper of the ACR Ovarian-Adnexal Reporting and Data Systems MRI Committee. Journal of the American College of Radiology, 2021, 18, 713-729.	1.8	50
38	Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers, 2020, 12, 2994.	3.7	49
39	Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study. Journal of Urology, 2016, 196, 697-702.	0.4	47
40	Second-Opinion Interpretations of Gynecologic Oncologic MRI Examinations by Sub-Specialized Radiologists Influence Patient Care. European Radiology, 2016, 26, 2089-2098.	4.5	47
41	High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology, 2017, 285, 472-481.	7.3	46
42	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	7.3	46
43	Pleural Effusion Detected at CT prior to Primary Cytoreduction for Stage III or IV Ovarian Carcinoma: Effect on Survival. Radiology, 2011, 258, 776-784.	7.3	44
44	MRI of ovarian masses. Journal of Magnetic Resonance Imaging, 2013, 37, 265-281.	3.4	43
45	Volume-based quantitative FDC PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. European Radiology, 2015, 25, 3348-3353.	4.5	43
46	Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis. European Radiology, 2020, 30, 5560-5577.	4.5	42
47	Radiomics and radiogenomics in ovarian cancer: a literature review. Abdominal Radiology, 2021, 46, 2308-2322.	2.1	41
48	The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecologic Oncology, 2013, 129, 586-592.	1.4	40
49	From Staging to Prognostication. Magnetic Resonance Imaging Clinics of North America, 2017, 25, 611-633.	1.1	40
50	The Value of MR Imaging When the Site of Uterine Cancer Origin Is Uncertain. Radiology, 2011, 258, 785-792.	7.3	39
51	Value of a Standardized Lexicon for Reporting Levels of Diagnostic Certainty in Prostate MRI. American Journal of Roentgenology, 2014, 203, W651-W657.	2.2	39
52	Multiphasic contrast-enhanced MRI: Single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. Journal of Magnetic Resonance Imaging, 2013, 37, 1160-1167.	3.4	35
53	The Diagnostic Performance of MRI for Detection of Extramural Venous Invasion in Colorectal Cancer: A Systematic Review and Meta-Analysis of the Literature. American Journal of Roentgenology, 2019, 213, 575-585.	2.2	35
54	Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3+4 prostate cancer. European Radiology, 2014, 24, 3161-3170.	4.5	34

#	ARTICLE	IF	CITATIONS
55	PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. <i>Nuclear Medicine and Biology</i> , 2014, 41, 410-418.	0.6	33
56	Reducing the influence of b ⁰ -value selection on diffusion-weighted imaging of the prostate: Evaluation of a revised monoexponential model within a clinical setting. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 660-668.	3.4	32
57	Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. <i>American Journal of Roentgenology</i> , 2017, 208, 849-853.	2.2	31
58	Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management. <i>Abdominal Radiology</i> , 2017, 42, 2488-2512.	2.1	30
59	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>European Urology Oncology</i> , 2019, 2, 605-616.	5.4	30
60	Magnetic Resonance Imaging/Positron Emission Tomography Provides a Roadmap for Surgical Planning and Serves as a Predictive Biomarker in Patients With Recurrent Gynecological Cancers Undergoing Pelvic Exenteration. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1512-1519.	2.5	28
61	Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng/ml following prostatectomy: How much information can conventional imaging provide?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 482.e5-482.e10.	1.6	28
62	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. <i>Journal of Urology</i> , 2020, 203, 1117-1121.	0.4	28
63	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. <i>Radiology</i> , 2021, 299, 494-507.	7.3	26
64	Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. <i>European Radiology</i> , 2020, 30, 4306-4316.	4.5	25
65	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	7.0	25
66	Anatomic segmentation improves prostate cancer detection with artificial neural networks analysis of ¹ H magnetic resonance spectroscopic imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 1414-1421.	3.4	24
67	Healthy Tissue Uptake of ⁶⁸ Ga-Prostate-Specific Membrane Antigen, ¹⁸ F-DCFPyL, ¹⁸ F-Fluoromethylcholine, and ¹⁸ F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	5.0	23
68	Accelerating Prostate Diffusion-weighted MRI Using a Guided Denoising Convolutional Neural Network: Retrospective Feasibility Study. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e200007.	5.8	23
69	The Diagnostic Performance of the Length of Tumor Capsular Contact on MRI for Detecting Prostate Cancer Extracapsular Extension: A Systematic Review and Meta-Analysis. <i>Korean Journal of Radiology</i> , 2020, 21, 684.	3.4	23
70	Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2020, 214, 597-604.	2.2	21
71	Reproducibility and Repeatability of Semiquantitative ¹⁸ F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1516-1523.	5.0	20
72	ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Endometrial Cancer. <i>Journal of the American College of Radiology</i> , 2020, 17, S472-S486.	1.8	20

#	ARTICLE	IF	CITATIONS
73	MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer. <i>European Journal of Radiology</i> , 2013, 82, e775-e781.	2.6	19
74	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸ F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1050-1056.	5.0	19
75	Imaging Features of Uncommon Gynecologic Cancers. <i>American Journal of Roentgenology</i> , 2015, 205, 1346-1359.	2.2	17
76	Intradiverticular bladder cancer: CT imaging features and their association with clinical outcomes. <i>Clinical Imaging</i> , 2015, 39, 94-98.	1.5	17
77	Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. <i>Abdominal Radiology</i> , 2017, 42, 271-277.	2.1	17
78	Contribution of Radiology to Staging of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 294-301.	4.6	17
79	Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 16.	1.5	17
80	Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. <i>European Radiology</i> , 2015, 25, 1294-1302.	4.5	16
81	Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 554-559.	1.4	16
82	Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 663.	2.6	16
83	Left Gastric Artery Aneurysm: Successful Embolization with Ethylene Vinyl Alcohol Copolymer (Onyx). <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 418-421.	2.0	13
84	Primary seminal vesicle adenocarcinoma. <i>Clinical Imaging</i> , 2011, 35, 480-482.	1.5	13
85	The performance of PI-RADSV2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer. <i>Abdominal Radiology</i> , 2017, 42, 1968-1974.	2.1	13
86	Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study. <i>Cancer Imaging</i> , 2021, 21, 24.	2.8	13
87	Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 1-10.	1.1	12
88	Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. <i>Journal of Urology</i> , 2021, 205, 1055-1062.	0.4	12
89	Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes. <i>Radiology</i> , 2022, 302, 595-602.	7.3	12
90	Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound. <i>Abdominal Radiology</i> , 2020, 45, 3882-3895.	2.1	11

#	ARTICLE	IF	CITATIONS
91	Role of MRI in the diagnosis and management of prostate cancer. <i>Future Oncology</i> , 2015, 11, 2757-2766.	2.4	10
92	Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e9-530.e14.	1.6	10
93	Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. <i>World Journal of Radiology</i> , 2015, 7, 184.	1.1	9
94	The expanding landscape of diffusion-weighted MRI in prostate cancer. <i>Abdominal Radiology</i> , 2016, 41, 854-861.	2.1	8
95	Contemporary Management of Hemorrhage After Minimally Invasive Radical Prostatectomy. <i>Urology</i> , 2019, 130, 120-125.	1.0	8
96	Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer. <i>Abdominal Radiology</i> , 2019, 44, 2864-2873.	2.1	8
97	Comparison of PI-RADS Versions 2.0 and 2.1 for MRI-based Calculation of the Prostate Volume. <i>Academic Radiology</i> , 2021, 28, 1548-1556.	2.5	8
98	The urachus revisited: multimodal imaging of benign & malignant urachal pathology. <i>British Journal of Radiology</i> , 2020, 93, 20190118.	2.2	8
99	ACR Appropriateness Criteria® Gestational Trophoblastic Disease. <i>Journal of the American College of Radiology</i> , 2019, 16, S348-S363.	1.8	7
100	The role of MRI in prostate cancer: current and future directions. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2022, 35, 503-521.	2.0	7
101	Prognostic Utility of MRI Features in Intradiverticular Bladder Tumor. <i>Academic Radiology</i> , 2022, 29, 219-228.	2.5	6
102	Quantitative versus Subjective Analysis of Dynamic Contrast-enhanced MRI for O-RADS?. <i>Radiology</i> , 2022, 303, 576-577.	7.3	6
103	MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	6
104	Association Between Penile Dynamic Contrast-enhanced MRI-derived Quantitative Parameters and Self-reported Sexual Function in Patients with Newly Diagnosed Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2014, 11, 2581-2588.	0.6	5
105	Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 432-434.	0.5	5
106	ACR Appropriateness Criteria® Staging and Follow-up of Vulvar Cancer. <i>Journal of the American College of Radiology</i> , 2021, 18, S212-S228.	1.8	4
107	Residual Prostate Tissue After Radical Prostatectomy: Acceptable Surgical Complication or Treatment Failure?. <i>Urology</i> , 2010, 76, 1136-1137.	1.0	3
108	ACR Appropriateness Criteria® Postmenopausal Subacute or Chronic Pelvic Pain. <i>Journal of the American College of Radiology</i> , 2018, 15, S365-S372.	1.8	3

#	ARTICLE	IF	CITATIONS
109	Response. Radiology, 2015, 274, 625.	7.3	3
110	The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. Imaging in Medicine, 2011, 3, 333-343.	0.0	2
111	The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 701-707.	6.4	2
112	Magnetic Resonance Imaging-Targeted Prostate Biopsies: Now Is the Time to START. European Urology, 2013, 64, 553-554.	1.9	2
113	Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. Urology, 2018, 119, 55-61.	1.0	2
114	Doctor, a patient is on the phone asking about the endorectal coil!. Abdominal Radiology, 2020, 45, 4003-4011.	2.1	2
115	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer, 2022, 20, 69-79.	1.9	2
116	Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors after Cisplatin-Based Chemotherapy. JNCI Cancer Spectrum, 0, , .	2.9	2
117	Ovarian Cancer from Anatomy to Functional Imaging. Current Radiology Reports, 2015, 3, 1.	1.4	1
118	Emergency room imaging in patients with genitourinary cancers: analysis of the spectrum of CT findings and their relation to patient outcomes. Emergency Radiology, 2020, 27, 413-421.	1.8	1
119	Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e17-495.e24.	1.6	1
120	Author Reply. Urology, 2017, 102, 172.	1.0	0
121	Advances in imaging. Nature Reviews Urology, 2018, 15, 81-82.	3.8	0
122	Commentary on "Prostate-Specific Membrane Antigen PET-CT in Patients With High-Risk Prostate Cancer Before Curative-Intent Surgery or Radiotherapy (proPSMA): a Prospective, Randomised, Multicentre Study". American Journal of Roentgenology, 2021, 216, 310-310.	2.2	0
123	Emergency room imaging in pediatric patients with cancer: analysis of the spectrum and frequency of imaging modalities and findings in a tertiary cancer center and their relationship with survival. Cancer Imaging, 2021, 21, 51.	2.8	0
124	BJR female genitourinary oncology special feature: introductory editorial. British Journal of Radiology, 2021, 94, 20219003.	2.2	0
125	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.4	0
126	Abbreviated MR Protocols in Prostate MRI. Life, 2022, 12, 552.	2.4	0